HomeCompareBPTS vs PEP

BPTS vs PEP: Dividend Comparison 2026

BPTS yields 24.33% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $47.0K in total portfolio value· pulled ahead in Year 10
10 years
BPTS
BPTS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full BPTS calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — BPTS vs PEP

📍 PEP pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPTSPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPTS + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPTS pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPTS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $43,715.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPTS + PEP for your $10,000?

BPTS: 50%PEP: 50%
100% PEP50/50100% BPTS
Portfolio after 10yr
$118.4K
Annual income
$36,160.81/yr
Blended yield
30.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

BPTS
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$15.00
+82.5% upside vs current
Range: $15.00 — $15.00
Altman Z
-13.4
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPTS buys
0
PEP buys
0
No recent congressional trades found for BPTS or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPTSPEP
Forward yield24.33%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$94.9K$141.9K
Annual income after 10y$10,445.94$61,875.67
Total dividends collected$59.3K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$15.00$172.43

Year-by-year: BPTS vs PEP ($10,000, DRIP)

YearBPTS PortfolioBPTS Income/yrPEP PortfolioPEP Income/yrGap
1$13,133$2,433.09$10,849$509.42+$2.3KBPTS
2$17,039$2,986.35$11,969$750.47+$5.1KBPTS
3$21,852$3,621.00$13,500$1,124.14+$8.4KBPTS
4$27,722$4,340.18$15,680$1,721.66+$12.0KBPTS
5$34,809$5,145.80$18,929$2,715.34+$15.9KBPTS
6$43,284$6,038.47$24,023$4,450.80+$19.3KBPTS
7$53,331$7,017.47$32,510$7,669.92+$20.8KBPTS
8$65,145$8,080.76$47,709$14,093.60+$17.4KBPTS
9$78,930$9,225.06$77,415$28,083.48+$1.5KBPTS
10← crossover$94,901$10,445.94$141,922$61,875.67$47.0KPEP

BPTS vs PEP: Complete Analysis 2026

BPTSStock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Full BPTS Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this BPTS vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPTS vs SCHDBPTS vs JEPIBPTS vs OBPTS vs KOBPTS vs MAINBPTS vs MOBPTS vs PMBPTS vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.